clinical trial · NCT07541898
Effects of Berberine on Cardiometabolic Outcomes
University of Central Lancashire·N/A·not yet recruiting·n = 40
Cardiometabolic SyndromeBerberinePlacebo
brief summary
Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Berberine may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.
started
Jul 1, 2026
primary completion
Aug 1, 2028
completion
Jan 1, 2029
last updated
Apr 21, 2026
official title
Effects of Berberine Supplementation on Cardiometabolic Parameters
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol